Vasopressin is a Peptide owned by Endo International, and is involved in 2 clinical trials, of which 1 was completed, and 1 is planned.
Vasopressin is an agonist of arginine vasopressin receptor 1A, arginine vasopressin receptor 1B, and arginine vasopressin receptor 2. The vasoconstrictive effects are mediated by vascular V1 receptors. Vascular V1 receptors are directly coupled to phopholipase C, resulting in release of calcium, leading to vasoconstriction. It arrests bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.
The revenue for Vasopressin is expected to reach a total of $4.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Vasopressin NPV Report.
Vasopressin is currently owned by Endo International.
Vasopressin (Vasostrict) is a vasoconstrictor agents and an anti diuretic hormone. It is formulated as solution for intravenous route of administration. It is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.
Endo International Overview
Endo International (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceuticals, generic pharmaceuticals, sterile injectables and other products through its operating companies. It sells generic products in the US in various categories including urology, pain management, central nervous system (CNS) disorders, immunosuppression, cancer, cardiovascular diseases and women’s health. The company offers branded pharmaceuticals for conditions related to urology, orthopedics, endocrine disorders and pain management. Endo also provides over-the-counter (OTC) products, which include dermatological products and anti-infectives. The company sells its products through independent wholesale distributors to retailers, government agencies, doctors, clinics, independent retail and specialty pharmacies and independent specialty distributors. Endo is headquartered in Dublin, Ireland.
The company reported revenues of (US Dollars) US$2,993.2 million for the fiscal year ended December 2021 (FY2021), an increase of 3.1% over FY2020. In FY2021, the company’s operating margin was 0.1%, compared to an operating margin of 17.3% in FY2020. The net loss of the company was US$613.3 million in FY2021, compared to a net profit of US$183.9 million in FY2020. The company reported revenues of US$541.7 million for the third quarter ended September 2022, a decrease of 4.8% over the previous quarter.
Quick View – Vasopressin
|Highest Development Stage|